Heterogeneity of IDH+ glioma metabolism evaluated by CSI
Benjamin C Rowland1, Min Zhou1, Huijun Liao1, Nils Arvold2, Raymond Y Huang3, and Alexander P Lin1
1Centre for Clinical Spectroscopy, Brigham and Women's Hospital, Boston, MA, United States, 2Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States, 3Radiology, Brigham and Women's Hospital, Boston, MA, United States
MR spectroscopy is a powerful technique for understanding tumour metabolism. Chemical shift imaging allows spatial variations in spectra to be observed at the cost of signal to noise and acquisition time. In this abstract we examine the heterogeneity of metabolite concentrations in both tumour and healthy tissue, in particular the onco-metabolite 2-hydroxyglutarate, to ascertain if the benefits of CSI outweigh the penalties.
This abstract and the presentation materials are available to members only;
a login is required.
